Home › Funds › Convergence Investment Partners, LLC › HALO

Convergence Investment Partners, LLC position in HALO

HALOZYME THERAPEUTICS INC · Health Care

Convergence Investment Partners, LLC reported holding 72,886 shares of HALO (HALOZYME THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$8.0M, representing 0.60% of its reported portfolio and ranking #43 among its reported holdings. Convergence Investment Partners, LLC has disclosed HALO holdings in 10 of the last 12 reported quarters, going back to Q4 2023.

Latest position (Q3 2026)72.89K sh
Reported value held$8.05M
Portfolio Weight0.60%
First reportedQ4 2023
Last changeNew
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Convergence Investment Partners, LLC's HALO position evolved

Convergence Investment Partners, LLC first disclosed a stake in HALO in Q4 2023 at 7,008 shares (US$259K). The position peaked in Q3 2026 at 72,886 shares, worth US$8.0M. Across 10 filings, Convergence Investment Partners, LLC increased the stake 4 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 72,886 shares valued at US$8.0M. Notable position changes include a 26% increase in Q4 2024 (shares rose 33% over the following quarter), a 27% trim in Q3 2025 (shares fell 8% over the following quarter), a 54% increase in Q4 2025 (shares fell 4% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2023 7.01K $259.00K New
Q2 2024 26.25K $1.37M New
Q3 2024 27.56K $1.58M Add
Q4 2024 34.71K $1.66M Add
Q1 2025 28.54K $1.82M Reduce
Q2 2025 27.48K $1.43M Reduce
Q3 2025 20.09K $1.47M Reduce
Q4 2025 30.85K $2.08M Add
Q1 2026 37.60K $2.43M Add
Q3 2026 72.89K $8.05M New

Dots on the line are colored by change type; missing quarters mean no position was reported.

About HALO and 13F data

HALO (HALOZYME THERAPEUTICS INC) is a Health Care company. 45 other funds we track also report a position in HALO — the largest reported positions include CONGRESS ASSET MANAGEMENT CO (US$251.9M), SNYDER CAPITAL MANAGEMENT L P (US$187.5M), WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC (US$178.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding HALO

All HALO fund holders →

FAQ

How long has Convergence Investment Partners, LLC held HALO?

Convergence Investment Partners, LLC has disclosed HALO holdings in 10 of the last 12 reported quarters, going back to Q4 2023.

What is Convergence Investment Partners, LLC's current position in HALO?

As of Q3 2026, Convergence Investment Partners, LLC holds 72.89K shares of HALO (HALOZYME THERAPEUTICS INC), valued at $8.05M, representing 0.60% of its reported portfolio and ranking #43.

Has Convergence Investment Partners, LLC been buying or selling HALO?

In the latest 13F filing (Q3 2026), Convergence Investment Partners, LLC newly opened its position in HALO. The position peaked in Q3 2026 at 72.89K shares.

Which other funds hold HALO?

Other major institutional holders of HALO include CONGRESS ASSET MANAGEMENT CO, SNYDER CAPITAL MANAGEMENT L P, WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC, among 45 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.